Simcere Pharmaceutical Group (HKG:2096) renewed two key agreements set to expire on Dec. 31 including a three-year Diagnostics R&D Project Service Framework Agreement with Jiangsu Medical Diagnostics from January 1, according to a Monday filing with the Hong Kong bourse.
Similarly, a property lease and services framework with Nanjing BioSciKin Technology will offer office, laboratory, and staff facilities as well as logistical support.
Both transactions are classified as continuing connected transactions under Hong Kong's Listing Rules.